Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, ON.
ices, Toronto, ON.
Curr Oncol. 2020 Apr;27(2):e216-e221. doi: 10.3747/co.27.5629. Epub 2020 May 1.
After surgery for early-stage breast cancer (bca), adjuvant radiotherapy (rt) decreases the risk of locoregional recurrence and death from bca. It is unclear whether delays to the initiation of adjuvant rt are associated with inferior survival outcomes.
This population-based retrospective cohort study included a random sample of 25% of all women with stage i or ii bca treated with adjuvant rt in Ontario between 1 September 2001 and 31 August 2002, when, because of capacity issues, wait times for radiation were abnormally long. Pathology reports were manually abstracted and deterministically linked to population-level administrative databases to obtain information about recurrence and survival outcomes. Cox proportional hazards modelling was used to evaluate the association between waiting time and survival outcomes. A composite survival outcome was used to ensure that all possible measurable harms of delay would be captured. The composite outcome, event-free survival, included locoregional recurrence, development of metastatic disease, and bca-specific mortality.
We identified 1028 women with stage i or ii bca who were treated with breast-conserving surgery and adjuvant rt. For the 599 women who were treated with adjuvant radiation without intervening chemotherapy, a waiting time of 12 weeks or more from surgery to the start of radiation appeared to be associated with worse event-free survival after a median follow-up of 7.2 years (hazard ratio for the composite outcome: 1.44; 95% confidence interval: 0.98 to 2.11; = 0.07). For the 429 women who received intervening adjuvant chemotherapy, a waiting time of 6 weeks or more from completion of chemotherapy to start of radiation was associated with worse event-free survival after a median follow-up of 7.4 years (hazard ratio: 1.50; 95% confidence interval: 1.00 to 2.22; = 0.047).
Delay to the initiation of adjuvant rt after breast-conserving surgery is associated with inferior bca survival outcomes. The good prognosis for patients with early-stage bca limits the statistical power to detect an effect of delay to rt. Given that there is no plausible advantage to delay, we agree with Mackillop that time to initiation of rt should be kept "as short as reasonably achievable."
早期乳腺癌(BCA)手术后,辅助放疗(RT)可降低局部区域复发和 BCA 死亡的风险。目前尚不清楚辅助 RT 起始时间的延迟是否与较差的生存结局有关。
本基于人群的回顾性队列研究纳入了 2001 年 9 月 1 日至 2002 年 8 月 31 日期间在安大略省接受辅助 RT 治疗的 I 期或 II 期 BCA 女性的随机样本的 25%,当时由于容量问题,放射治疗的等待时间异常延长。手动提取病理报告,并确定性地与人群水平的行政数据库相关联,以获取有关复发和生存结局的信息。使用 Cox 比例风险模型评估等待时间与生存结局之间的关联。使用复合生存结局来确保捕获所有可能的延迟可衡量的危害。复合结局(无事件生存)包括局部区域复发、转移性疾病的发展和 BCA 特异性死亡率。
我们确定了 1028 名接受保乳手术和辅助 RT 治疗的 I 期或 II 期 BCA 女性。对于 599 名接受辅助放疗而无介入化疗的女性,从手术到开始放疗的等待时间为 12 周或更长时间,中位随访 7.2 年后,无事件生存似乎较差(复合结局的危险比:1.44;95%置信区间:0.98 至 2.11; = 0.07)。对于接受辅助化疗的 429 名女性,从化疗完成到开始放疗的等待时间为 6 周或更长时间,中位随访 7.4 年后,无事件生存较差(危险比:1.50;95%置信区间:1.00 至 2.22; = 0.047)。
保乳手术后辅助 RT 起始时间的延迟与 BCA 生存结局较差有关。早期 BCA 患者的良好预后限制了检测延迟对 RT 影响的统计能力。鉴于延迟没有明显的优势,我们同意 Mackillop 的观点,即 RT 的起始时间应“尽可能短”。